From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver Pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and business process infrastructure for market access and therapy commercialization.
Solutions overview
IntegriChain delivers pharma’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, managed services and expert advisors to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
IntegriChain provides wide array of resources to help you navigate your journey to market access success.
Resources overview
We help all stakeholders in the pharmaceutical industry drive access. We do this through our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts and pricing, gross-to-net, channel, and patient services – unlocking strategic payer, provider, pharmacy and patient access insights for our life sciences customers.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, Market Access experts, analysts, technologies, and advisory professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
IntegriChain Director of Solution Engineering Dave Weiss and co-founder and Executive Vice President Josh Halpern explore best practices for estimating inventory when calculating gross-to-net to eliminate gross overstatements or understatements of pipeline liabilities that do not triangulate well with other channel commerce data sets. We will focus on real-world methodologies to avoid error risk in estimating the impact of downstream inventory on gross-to-net. In this webinar, you will learn about best practices for using auditor-approved downstream inventory data and analytics for preparing for loss of exclusivity (LOE), tightening gross-to-net reserves, and improving visibility to gross sales forecast risk.